Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer

We previously found that the gene encoding the Myelin and Lymphocyte protein, MAL, was among the most highly expressed genes in serous ovarian cancers from short‐term survivors (7 years). In the present study, we have found that this difference in expression is partially attributable to differences...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2010-03, Vol.126 (6), p.1378-1389
Hauptverfasser:	Lee, Paula S., Teaberry, Vanessa S., Bland, Amy E., Huang, Zhiqing, Whitaker, Regina S., Baba, Tsukasa, Fujii, Shingo, Secord, Angeles Alvarez, Berchuck, Andrew, Murphy, Susan K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Azacitidine - pharmacology Base Sequence Biological and medical sciences Cell Line, Tumor Cell Proliferation - drug effects chemoresistance Cisplatin - pharmacology Cisplatin - therapeutic use DNA Methylation Drug Resistance, Neoplasm - genetics epigenetic Epithelial Cells - pathology Female Female genital diseases Gene Expression Profiling Gene Expression Regulation, Neoplastic Gynecology. Andrology. Obstetrics Humans MAL Medical sciences Membrane Transport Proteins - genetics methylation Molecular Sequence Data Myelin and Lymphocyte-Associated Proteolipid Proteins Myelin Proteins - genetics Oligonucleotide Array Sequence Analysis ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Promoter Regions, Genetic - genetics Proteolipids - genetics Reverse Transcriptase Polymerase Chain Reaction Sequence Analysis, DNA - methods Survivors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!